1-(1-吡咯烷基甲基)环己胺 | 876717-44-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(1-吡咯烷基甲基)环己胺
• 英文名称: 1-(pyrrolidin-1-ylmethyl)cyclohexanamine
• 英文别名: 1-Pyrrolidin-1-ylmethyl-cyclohexylamine；1-(pyrrolidin-1-ylmethyl)cyclohexan-1-amine
• CAS: 876717-44-1
• 化学式: C₁₁H₂₂N₂
• 分子量: 182.309
• InChiKey: FFNSNUBYKYSWNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• WGK Germany：
  3

反应信息

• 作为产物：
  描述：

  1-(pyrrolidin-1-ylcarbonyl)cyclohexanamine hydrochloride 在 lithium aluminium tetrahydride 、 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 1-(1-吡咯烷基甲基)环己胺
  参考文献：
  名称：

  2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER

  摘要：

  公开号：

  EP1955697B1

文献信息

• Macrocyclic Spiro Pyrimidine Derivatives
  申请人：Liu Huaqing

  公开号：US20090233904A1

  公开（公告）日：2009-09-17

  Macrocyclic spiro pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

  本文描述了大环螺环嘧啶化合物、包含这种化合物的组合物、制备这些化合物的方法，以及利用这种化合物和组合物治疗和预防疾病、病况和障碍的方法。
• MACROCYCLIC PYRIMIDINE DERIVATIVES
  申请人：Liu Huaqing

  公开号：US20090253678A1

  公开（公告）日：2009-10-08

  Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

  本文描述了大环嘧啶化合物、包含此类化合物的组合物、制备此类化合物的方法以及使用此类化合物和组合物治疗和预防疾病、病症和障碍的方法。
• 2-AMINOBENZAMIDE DERIVATIVE
  申请人：Kuramochi Takahiro

  公开号：US20090233900A1

  公开（公告）日：2009-09-17

  To provide a novel and excellent agent for treating or preventing nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like, based on the inhibitory action on the capsaicin receptor VR1 activation. The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the neighboring position of said amido group has a strong inhibitory action on VR1 activation and excellent pharmacological actions based on this and by finding that it can become an excellent agent for treating or preventing VR1-involved diseases such as nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like.

  本发明提供了一种基于对辣椒素受体VR1激活的抑制作用的新型优良药剂，用于治疗或预防伤害性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等疾病。本发明通过确认一种苯甲酰胺衍生物，其特征在于其苯环上的单环在酰胺基氮原子上被紧缩，其低烷基氨基或邻位于酰胺基的环基取代的氨基具有对VR1激活的强抑制作用和优良的药理作用，从而发现它可以成为治疗或预防伤害性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等VR1相关疾病的优良药剂。
• 2-aminobenzamide derivatives
  申请人：Astellas Pharma Inc.

  公开号：US08106190B2

  公开（公告）日：2012-01-31

  To provide a novel and excellent agent for treating or preventing nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like, based on the inhibitory action on the capsaicin receptor VR1 activation. The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the neighboring position of said amido group has a strong inhibitory action on VR1 activation and excellent pharmacological actions based on this and by finding that it can become an excellent agent for treating or preventing VR1-involved diseases such as nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like.

  为了提供一种新颖且优秀的药剂，用于治疗或预防嗜痛性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等，基于对辣椒素受体VR1激活的抑制作用。本发明通过确认一种苯甲酰胺衍生物，其特征在于其苯环上的单环在酰胺基团的氮原子上凝聚，并具有一个邻位取代环基的较低烷基氨基或氨基团，具有对VR1激活的强抑制作用和基于此的优异药理学作用，并发现它可以成为治疗或预防嗜痛性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等VR1相关疾病的优秀药剂。
• US8106190B2
  申请人：——

  公开号：US8106190B2

  公开（公告）日：2012-01-31